1,300
Views
0
CrossRef citations to date
0
Altmetric
Editorial

How can we prevent disease relapse in Graves’ orbitopathy after immunosuppressive treatment?

ORCID Icon &
Pages 269-274 | Received 04 May 2022, Accepted 07 Jul 2022, Published online: 13 Jul 2022

References

  • Campi I, Vannucchi G, Salvi M. THERAPY OF ENDOCRINE DISEASE: endocrine dilemma: management of Graves’ orbitopathy. Eur J Endocrinol. 2016;175:R117–R133.
  • Bartalena L. Graves’ orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J. 2013;2:259–269.
  • Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clinical Endocrinol. 1997;47:9–14.
  • Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the european group on graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–275.
  • Bartalena L, Kahaly GJ, and Baldeschi L, et al. The 2021 European group on graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185:G43–G67.
  • Currò N, Covelli D, Vannucchi G, et al. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid. 2014;24:897–905.
  • Douglas RS, Kahaly GJ, and Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022;129:438–449.
  • Tanda ML, Gallo D, Ippolito S, et al. Treatment of moderate-to-severe and active Graves’ orbitopathy: a step forward from the OPTIC study. J Endocrinol Invest. 2020;43:1523–1525.
  • Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9:360–372.
  • Bartalena L, Marinò M, Marcocci C, et al. Teprotumumab for Graves’ orbitopathy and ototoxicity: moving problems from eyes to ears? J Endocrinol Invest. 2022;45:1455–1457.
  • Bartalena L, Wiersinga WM. Proposal for standardization of primary and secondary outcomes in patients with active, moderate-to-severe Graves’ orbitopathy. Eur J Endocrinol. 2020;9:3–16.
  • Terwee C, Wakelkamp I, Tan S, et al. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol. 2002;146:751–757.
  • Ponto KA, Pitz S, Pfeiffer N, et al. Quality of life and occupational disability in endocrine orbitopathy. Dtsch Arztebl Int. 2009;106:283–289.
  • Salvi M, Campi I. Medical treatment of Graves’ orbitopathy. Horm Metab Res. 2015;47:779–788.
  • Selva D, Chen C, King G. Late reactivation of thyroid orbitopathy. Clin Exp Ophthalmol. 2004;32:46–50.
  • Patel P, Khandji J, Kazim M. Recurrent Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2015;31(6):445–448.
  • Wiersinga W, Žarković M, Bartalena L, et al. Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism. Eur J Endocrinol. 2018;178:635–643.
  • Baldeschi L, Lupetti A, Vu P, et al. Reactivation of Graves’ orbitopathy after rehabilitative orbital decompression. Ophthalmology. 2007;114:1395–1402.
  • Lanzolla G, Sabini E, and Leo M, et al. Statins for Graves’ orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol. 2021;9:733–742.
  • Bartalena L, Piantanida E, and Gallo D, et al. Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy. Front Endocrinol. 2020;11:615993.
  • Hegediüs L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves’ ophthalmopathy. J Endocrinol Invest. 2004;27:265–271.
  • Rigotti NA, Kruse GR, Livingstone-Banks J, et al. Treatment of tobacco smoking: a review. JAMA. 2022;327:566–577.
  • Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–78.
  • Vannucchi G, Covelli D, Campi I, et al. Prevention of orbitopathy by oral or intravenous steroid prophylaxis in short duration Graves’ disease patients undergoing radioiodine ablation: a prospective randomized control trial study. Thyroid. 2019;29:1828–1833.
  • Lanzolla G, Marinò M, Marcocci C. Selenium in the treatment of Graves’ hyperthyroidism and eye disease. Front Endocrinol. 2021;11:608428.
  • Zang S, Ponto KA, Kahaly GJ. Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320–332.
  • Sobel RK, Aakalu VK, Vagefi MR, et al. Orbital radiation for thyroid eye disease: a report by the American Academy of Ophthalmology. Ophthalmology. 2022;129:450–455.
  • Vannucchi G, Covelli D, and Campi I, et al. The therapeutic outcome to intravenous steroid therapy for active Graves’ orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. Eur J Endocrinol. 2013;170:55–61.
  • Bartalena L, Veronesi G, Krassas GE, et al. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest. 2017;40:547–553.
  • Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422–431.
  • Stan MN, Salvi M. MANAGEMENT OF ENDOCRINE DISEASE: rituximab therapy for Graves’ orbitopathy - lessons from randomized control trials. Eur J Endocrinol. 2017;176:R101–R109.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.